Search the database for deliberate release of GM medicinal products
Displaying 1 - 2 of 2
| EU record number | Title | Company / Sponsor | Treated organism | Genetic modification |
|---|---|---|---|---|
| Only notified under the "contained use" procedure. Dossier submitted on . | A single-arm, open-label, multi-centre, phase I/II study evaluating the safety and clinical activity of QEL-001, an autologous CAR T regulatory cell treatment targeting HLA-A2, in HLA-A2/ A28neg patients that have received an HLA-A2pos liver transplant | Quell Therapeutics Limited | Humans | BCMA CAR; shRNA CD3ζ; tCD34 |
| Only notified under the "contained use" procedure. Dossier submitted on . | A phase I study in patients with recurrent or metastatic squamous cell carcinoma of the head and neck using SCH 58500 (rAd/p53) administered by single intratumoral injection | Schering Plough NV/SA | Humans | Wild-type p53 |